
Episode #5
Improving Patient Outcomes: The AI Opportunity in Commercial Pharma
In this episode of Enterprise Alchemists, Dominic Wellington and Jeremiah Stone are joined by Greg Higgins, Strategy and Business Development Leader at ALLOT, a company focused on agentic AI for commercial pharma. Greg brings four decades of pharmaceutical industry experience to a conversation about why AI is simultaneously one of the most promising and most frustrated technologies in healthcare right now. The discussion covers why pharma has more AI pilots running than anyone knows what to do with — and why almost none of them are making it to production. The culprit, Greg argues, isn't the technology. It's governance, guardrails, and the unglamorous work of business process re-engineering that has to happen before AI can do anything useful. From the emergence of direct-to-patient pharmacy models like Lilly Direct, to a detailed case study in IVF treatment access and health inequalities, to the UK's MHRA already deploying AI for drug assessment — this is a conversation that takes AI out of the abstract and grounds it firmly in the mechanics of how healthcare is actually delivered, funded, and regulated.

